25 Sarcoma 1 1 0 13 13 8 http://clinicaltrials.dfhcc.harvard.edu/trials/8 Trial of Dasatinib in Advanced Sarcomas This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma Phase 2 1117 http://clinicaltrials.dfhcc.harvard.edu/trials/1117 Bevacizumab and Radiation Therapy for Sarcomas The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab in combination with radiation for sarcomas is still under investigation. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma Phase 2 145 http://clinicaltrials.dfhcc.harvard.edu/trials/145 Phase 2 Study in Patients With MiT Tumors This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. MiT tumors include clear cell sarcoma, alveolar soft parts sarcoma, and translocation associated renal cell carcinoma. Recruiting 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma Phase 2 1284 http://clinicaltrials.dfhcc.harvard.edu/trials/1284 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg RATIONALE: Image-guided radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a lower dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying the side effects and how well image-guided radiation therapy works in treating patients with primary soft tissue sarcoma of the shoulder, arm, hip, or leg. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma Phase 2 1291 http://clinicaltrials.dfhcc.harvard.edu/trials/1291 Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma Phase 1/Phase 2 324 http://clinicaltrials.dfhcc.harvard.edu/trials/324 Collecting and Storing Biological Samples From Patients With Ewing Sarcoma RATIONALE: Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma N/A 1178 http://clinicaltrials.dfhcc.harvard.edu/trials/1178 Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma The objective of this study is to facilitate access to trabectedin for eligible previously treated subjects with soft tissue sarcoma (STS), who cannot be expected to benefit from currently available therapeutic options for treatment of STS but who may benefit from treatment with trabectedin. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 1197 http://clinicaltrials.dfhcc.harvard.edu/trials/1197 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus) The purpose of this study is to determine whether maintenance therapy with oral AP23573 (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result in clinically significant improvement in progression-free survival as compared to oral placebo. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 1202 http://clinicaltrials.dfhcc.harvard.edu/trials/1202 A Study of R1507 in Patients With Recurrent or Refractory Sarcoma. This single arm study will evaluate the efficacy and safety of R1507 in patients with recurrent or refractory sarcoma. Five cohorts of sarcoma patients will be studied in parallel: Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, and other sarcomas. All patients will receive R1507 9mg/kg i.v. weekly. The anticipated time on study treatment is until disease progression or unacceptable adverse events, and the target sample size is 100-500 individuals. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 1237 http://clinicaltrials.dfhcc.harvard.edu/trials/1237 A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-Based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS) A randomized, multicenter, Phase III trial to evaluate the effectiveness of trabectedin versus standard doxorubicin-based chemotherapy (DXCT) as first-line treatment of patients with advanced TRS, by comparing progression-free survival (PFS) in the two treatment arms. Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 1250 http://clinicaltrials.dfhcc.harvard.edu/trials/1250 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 1430 http://clinicaltrials.dfhcc.harvard.edu/trials/1430 Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone To determine how safe denosumab is in treating subjects with giant cell tumor of bone Recruiting 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma 1431 http://clinicaltrials.dfhcc.harvard.edu/trials/1431 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and best dose of zoledronic acid when given together with combination chemotherapy in treating patients with newly diagnosed metastatic osteosarcoma. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 25 Sarcoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/25-sarcoma